Transitional Care Programs for Patients With Rheumatic Diseases: Review of the Literature

Castrejón, Isabel

doi:10.1016/j.reumae.2011.06.001

Cited by 10 publications

(8 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study assessing the importance of transition to adult rheumatologic care in young people with JIA concluded that the maintenance of JIA diagnosis and DMARD therapy depended on the use of specialized care services [ 20 ]. Nowadays, young people with rheumatic diseases have a greater rate of survival, although high morbidity persists that could be avoided, in part, with multidisciplinary management [ 21 ]. Recently, several professional groups and international agencies have attempted to create consensus recommendations and guidelines trying to improve this situation [ 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER

et al. 2018

View full text Add to dashboard Cite

BackgroundBiologic therapy has changed the prognosis of patients with juvenile idiopathic arthritis (JIA). The aim of this study was to examine the pattern of use, drug survival, and adverse events of biologics in patients with JIA during the period from diagnosis to adulthood.MethodsAll patients included in BIOBADASER (Spanish Registry for Adverse Events of Biological Therapy in Rheumatic Diseases), a multicenter prospective registry, diagnosed with JIA between 2000 and 2015 were analyzed. Proportions, means, and SDs were used to describe the population. Incidence rates and 95% CIs were calculated to assess adverse events. Kaplan-Meier analysis was used to compare the drug survival rates.ResultsA total of 469 patients (46.1% women) were included. Their mean age at diagnosis was 9.4 ± 5.3 years. Their mean age at biologic treatment initiation was 23.9 ± 13.9 years. The pattern of use of biologics during their pediatric years showed a linear increase from 24% in 2000 to 65% in 2014. Biologic withdrawal for disease remission was higher in patients who initiated use biologics prior to 16 years of age than in those who were older (25.7% vs 7.9%, p < 0.0001). Serious adverse events had a total incidence rate of 41.4 (35.2–48.7) of 1000 patient-years. Patients younger than 16 years old showed significantly increased infections (p < 0.001).ConclusionsSurvival and suspension by remission of biologics were higher when these compounds were initiated in patients with JIA who had not yet reached 16 years of age. The incidence rate of serious adverse events in pediatric vs adult patients with JIA treated with biologics was similar; however, a significant increase of infection was observed in patients under 16 years old.Electronic supplementary materialThe online version of this article (10.1186/s13075-018-1728-3) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In any case, account must be taken of the patient's personality and health status, especially in terms of physical, psychosexual, social and professional maturity [14,15]. In the conditions of healthcare and education systems in Poland, it must be borne in mind that the preferred age of transition coincides with intensive school education, and the high level of anxiety related to the Matura examinations examinations, as well professional or educational choices.…”

Section: Preparation Of Patients For the Transition From Paediatric Tmentioning

confidence: 99%

“…Recommendations for patient care in adolescence can facilitate transition to adult care [11,13,15]. Mutual trust and respect in the patientphysician relationship is one of the cornerstones of proper patient care.…”

Section: Recommendations For Transitional Carementioning

confidence: 99%

“…It should be accompanied by the transfer of medical records (CT Passport), establishment of a treatment plan, and provision of contact details (phone number, e-mail address of the paediatrician). At best, physicians / patient management team should liaise closely to review the case [15]. Also, patients should not be excessively and repeatedly investigated during the transitional period.…”

Section: Transfer Of Medical Recordsmentioning

confidence: 99%

See 1 more Smart Citation

Problems of Patients with Cystic Fibrosis during Transition to Adulthood

Opoka-Winiarska

Cofta

Mazurek

et al. 2015

Advances in Respiratory Medicine

View full text Add to dashboard Cite

The proper care of cystic fibrosis patients extends over their lifetime. More than half of the children with the disease die before adulthood. An important element in the patient's care is a time of transition from a paediatric to the care of an internist and the patient's acceptance of this necessity. Transition from paediatric care to an internist should be adequately prepared. It is not only a question of transfer of medical records, but also careful preparation of patients for such transition. The patients expect not only continuity of care but also the introduction to the management with the disease. The creation of a base for specialist hospital treatment for exacerbation of the disease at the adulthood is an important element in the care of these patients. The problem has been solved in the children group, but is still waiting for solution in adults with cystic fibrosis. It has been proven that care in the centres carried out by a specialized team ensures longer life and better quality of life of these patients. The paper is an overview of these two important elements of care of adults with cystic fibrosis.

show abstract

“…Jednocześnie przewlekła choroba ogranicza ich sprawność fizyczną i umiejętność radzenia sobie w życiu. Proces "przejścia" może spowodować zaostrzenie objawów zapalenia [7][8][9][10].…”

Section: Linie (Transition For Teenagers and Young Adults With Arthriunclassified

Continuity of monitoring the rheumatic diseases course in patients after 18 years of age – the point of view of internist

Zimmermann-Górska¹

2013

Reumatologia

View full text Add to dashboard Cite

Reumatologia 2013; 51/1 S t r e s z c z e n i eMłodzież w okresie dojrzewania i młodzi dorośli mogą chorować na postępujące, aktywne zapalne choroby reumatyczne, w szczególności na młodzieńcze idiopatyczne zapalenie stawów. Wymagają oni kontynuacji leczenia i przeniesienia spod opieki pediatrów pod opiekę lekarzy zajmujących się osobami dorosłymi. Proces "przeniesienia" powinien polegać na współpracy między tymi lekarzami, a także na samodzielnym udziale chorego, który znalazł się w nowej sytuacji. Niezwykle ważne jest przekazanie odpowiedniej dokumentacji. S u m m a r yAdolescents and young patients may have ongoing problems with active rheumatic diseases, particularly with juvenile idiopathic arthritis. They require continuation of care and transfer from pediatric to adult services. The process of "transition" ought to include collaboration between pediatric and adult healthcare providers as well as involvement the young people themselves. The exact documentation is crucial for transitional care.A Ad dr re es s d do o k ko or re es sp po on nd de en nc cj ji i: :prof. dr hab. n. med. Irena Zimmermann-Górska,

show abstract

Transitional Care Programs for Patients With Rheumatic Diseases: Review of the Literature

Cited by 10 publications

References 35 publications

Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER

Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER

Problems of Patients with Cystic Fibrosis during Transition to Adulthood

Continuity of monitoring the rheumatic diseases course in patients after 18 years of age – the point of view of internist

Contact Info

Product

Resources

About